NO965160L - New farnesyl transferase inhibitors, their preparation and pharmaceutical compositions containing the compounds - Google Patents

New farnesyl transferase inhibitors, their preparation and pharmaceutical compositions containing the compounds

Info

Publication number
NO965160L
NO965160L NO965160A NO965160A NO965160L NO 965160 L NO965160 L NO 965160L NO 965160 A NO965160 A NO 965160A NO 965160 A NO965160 A NO 965160A NO 965160 L NO965160 L NO 965160L
Authority
NO
Norway
Prior art keywords
radical
alkyl
optionally substituted
general formula
carbon atoms
Prior art date
Application number
NO965160A
Other languages
Norwegian (no)
Other versions
NO965160D0 (en
Inventor
Bernard Baudoin
Christopher Burns
Alain Commercon
Jean-Dominique Guitton
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9407116A external-priority patent/FR2721021B1/en
Priority claimed from FR9412338A external-priority patent/FR2725717B1/en
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of NO965160D0 publication Critical patent/NO965160D0/en
Publication of NO965160L publication Critical patent/NO965160L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Abstract

Novel farnesyl transferase inhibitors of general formula (I), their preparation and pharmaceutical compositions containing same. In general formula (I), R1 is Y-S-A1 -(Y is a hydrogen atom, an amino acid residue, a fatty acid residue, an alkyl or alkoxycarbonyl radical or an R4-S radical in which R4 is an alkyl radical containing 1-4 carbon atoms optionally substituted by a phenyl radical or a radical of general formula (II), in which A1, X1, Y1, R'1, R2, R'2 and R are defined as follows: A1 is an alkylene radical containing 1-4 carbon atoms optionally a substituted at alpha in the grouping >C(X1)(Y1) with an amino or alkylamino, dialkylamino, alkanylamino or alkoxycarbonylamino radical), X1 and Y1 are each a hydrogen atom or form together with the carbon atom to which they are connected a >C=O grouping, R'1 is hydrogène or methyl, R2 is an alkyl, alkenyl or alkynyl radical containing 1-6 carbon atoms optionally substituted by hydroxy, alkoxy, mercapto, alkylthio, alkylsulfinyl or alkylsulfonyl, with the proviso that when R2 is an alkyl radical substituted by a hydroxy radical, R2 can form a lactone with the carboxy radical at alpha . R'2 is hydrogen or methyl and R is a hydrogen atom or an optionally substituted alkyl radical or an optionally substituted phenyl radical, whith the proviso that the radical (a) is in position 5 or 6 of the naphthyl ring. These novel products have anti-cancer properties.
NO965160A 1994-06-10 1996-12-03 New farnesyl transferase inhibitors, their preparation and pharmaceutical compositions containing the compounds NO965160L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9407116A FR2721021B1 (en) 1994-06-10 1994-06-10 New farnesyl transferase inhibitors, their preparation and the pharmaceutical compositions containing them.
FR9412338A FR2725717B1 (en) 1994-10-17 1994-10-17 NOVEL FARNESYL TRANSFERASE INHIBITORS, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
PCT/FR1995/000739 WO1995034535A1 (en) 1994-06-10 1995-06-07 Novel farnesyl transferase inhibitors, their preparation and pharmaceutical compositions containing same

Publications (2)

Publication Number Publication Date
NO965160D0 NO965160D0 (en) 1996-12-03
NO965160L true NO965160L (en) 1996-12-03

Family

ID=26231226

Family Applications (1)

Application Number Title Priority Date Filing Date
NO965160A NO965160L (en) 1994-06-10 1996-12-03 New farnesyl transferase inhibitors, their preparation and pharmaceutical compositions containing the compounds

Country Status (15)

Country Link
EP (1) EP0764149B1 (en)
JP (1) JPH10501259A (en)
CN (1) CN1150419A (en)
AT (1) ATE175958T1 (en)
AU (1) AU2742195A (en)
BR (1) BR9508187A (en)
CA (1) CA2192389A1 (en)
CZ (1) CZ361996A3 (en)
DE (1) DE69507476D1 (en)
FI (1) FI964920A (en)
NO (1) NO965160L (en)
PL (1) PL317580A1 (en)
SK (1) SK158196A3 (en)
TW (1) TW365602B (en)
WO (1) WO1995034535A1 (en)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6265603B1 (en) 1997-02-27 2001-07-24 Eisai Co., Ltd. Inhibitors of isoprenyl transferase
GB2323842A (en) * 1997-04-04 1998-10-07 Ferring Bv Pyridine derivatives
GB2323841A (en) * 1997-04-04 1998-10-07 Ferring Bv Group Holdings Pyridine derivatives with anti-tumor and anti-inflammatory activity
US6071547A (en) * 1998-10-08 2000-06-06 Superior Nutrition Corporation Textured dry mix instant nutritional drink
US6486202B1 (en) 2001-04-13 2002-11-26 Eisai Company, Limited Inhibitors of isoprenyl transferase
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
PL2010528T3 (en) 2006-04-19 2018-03-30 Novartis Ag 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling
JP5489333B2 (en) 2006-09-22 2014-05-14 メルク・シャープ・アンド・ドーム・コーポレーション Methods of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
PL2336120T3 (en) 2007-01-10 2014-12-31 Msd Italia Srl Combinations containing amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
BRPI0808523A2 (en) 2007-03-01 2014-08-19 Novartis Vaccines & Diagnostic PIM KINASE INHIBITORS AND METHODS OF USE
KR20100017866A (en) 2007-05-21 2010-02-16 노파르티스 아게 Csf-1r inhibitors, compositions, and methods of use
CA2690191C (en) 2007-06-27 2015-07-28 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
CN102480966B (en) 2009-06-12 2015-09-16 达娜-法勃肿瘤研究所公司 Heterocyclic compound merged and uses thereof
UA109417C2 (en) 2009-10-14 2015-08-25 Мерк Шарп Енд Доме Корп. Substituted piperidines, which improve activity of p53, and use thereof
CA2784807C (en) 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
WO2011115725A2 (en) 2010-03-16 2011-09-22 Dana-Farber Cancer Institute, Inc. Indazole compounds and their uses
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
EP2601293B1 (en) 2010-08-02 2017-12-06 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2012024170A2 (en) 2010-08-17 2012-02-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP3327125B1 (en) 2010-10-29 2020-08-05 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
US20140045847A1 (en) 2011-04-21 2014-02-13 Piramal Enterprises Limited Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
JP6106685B2 (en) 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Inhibitors of C-JUN-N-terminal kinase (JNK)
EP3453762B1 (en) 2012-05-02 2021-04-21 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
CA2882950A1 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2014063068A1 (en) 2012-10-18 2014-04-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
BR112015012295A8 (en) 2012-11-28 2023-03-14 Merck Sharp & Dohme USE OF A WEE1 INHIBITOR, E, KIT TO IDENTIFY A PATIENT WITH CANCER
CN105073746B (en) 2012-12-20 2017-03-22 默沙东公司 Substituted imidazopyridines as HDM2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
AU2014337122B2 (en) 2013-10-18 2019-01-03 Dana-Farber Cancer Institute, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
AU2014337044A1 (en) 2013-10-18 2016-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
KR20160102210A (en) 2013-12-27 2016-08-29 노버스 인터내쇼날 인코포레이티드 Ethoxylated surfactants
WO2015164604A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
JO3589B1 (en) 2014-08-06 2020-07-05 Novartis Ag Protein kinase c inhibitors and methods of their use
EP3236959A4 (en) 2014-12-23 2018-04-25 Dana Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
EP3273966B1 (en) 2015-03-27 2023-05-03 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
EP3347018B1 (en) 2015-09-09 2021-09-01 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
CN109071425B (en) * 2016-03-23 2021-01-15 陈裕仁 Farnesyl transferase inhibitors and uses thereof
JOP20190055A1 (en) 2016-09-26 2019-03-24 Merck Sharp & Dohme Anti-cd27 antibodies
JP7160833B2 (en) 2017-04-13 2022-10-25 サイロパ ビー．ブイ． anti-SIRP alpha antibody
US10584306B2 (en) 2017-08-11 2020-03-10 Board Of Regents Of The University Of Oklahoma Surfactant microemulsions
EP3706742B1 (en) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
EP3833668A4 (en) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2044333A1 (en) * 1990-06-12 1991-12-13 Jackson B. Gibbs Chemotherapeutic agents
US5352705A (en) * 1992-06-26 1994-10-04 Merck & Co., Inc. Inhibitors of farnesyl protein transferase
US5504212A (en) * 1992-10-29 1996-04-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase

Also Published As

Publication number Publication date
EP0764149A1 (en) 1997-03-26
CA2192389A1 (en) 1995-12-21
ATE175958T1 (en) 1999-02-15
FI964920A0 (en) 1996-12-09
WO1995034535A1 (en) 1995-12-21
JPH10501259A (en) 1998-02-03
SK158196A3 (en) 1997-07-09
EP0764149B1 (en) 1999-01-20
BR9508187A (en) 1997-08-12
CZ361996A3 (en) 1997-04-16
DE69507476D1 (en) 1999-03-04
NO965160D0 (en) 1996-12-03
PL317580A1 (en) 1997-04-14
AU2742195A (en) 1996-01-05
TW365602B (en) 1999-08-01
FI964920A (en) 1996-12-09
CN1150419A (en) 1997-05-21

Similar Documents

Publication Publication Date Title
NO965160D0 (en) New farnesyl transferase inhibitors, their preparation and pharmaceutical compositions containing the compounds
NO973222L (en) New farnesyl transferase inhibitors, their preparation and pharmaceutical preparations containing the inhibitors
DE69628559D1 (en) Carbonyl-piperaznyl und piperidinyl derivate zur hemmung farnesyl protein transferase
KR950032114A (en) Proline amide derivative
ES2137169T3 (en) NEW DERIVATIVES OF TIAZOLILBENZOFURANO, PROCEDURES FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM.
NO973608L (en) New farnesyl transferase inhibitors, their preparation and pharmaceutical preparations containing the compounds
CA2304713A1 (en) Biphenyl-5-alkanoic acid derivatives and use thereof
NO973607L (en) New farnesyl transferase inhibitors, their preparation and preparations containing the inhibitors
ES8301925A1 (en) Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids, salts thereof, pharmaceutical compositions containing the derivatives or salts, and the production of the same.
WO2004071388A3 (en) Medicinal compounds
ATE192038T1 (en) MEDICINAL COMPOSITION BASED ON DIOXABICYCLO(3.3.0)OCTANE DERIVATIVES
GB9308487D0 (en) Novel compounds
GR3001879T3 (en) Cytoprotective derivatives useful in ischemic diseases, their preparation and compositions containing them
ES8507090A1 (en) 1,5-Benzothiazepines with cardiovascular utility, and pharmaceutical compositions containing them
TW200508274A (en) Antioxidant and bisaminophenol derivative
IL69882A (en) Analgesia-effecting 5-hydroxytryptophan derivatives and pharmaceutical compositions comprising them
ZA944727B (en) Phosphonic acid compounds processes for preparing them and pharmaceutical compositions containing them
MX9606106A (en) Novel farnesyl transferase inhibitors, their preparation and pharmaceutical compositions containing same.
CY1106058T1 (en) STABLE COMPOSITIONS OF OXAPENEM-3-CARBOXYLIC ACIDS CO-LYOPHILOZING WITH PHARMACEUTICAL CARRIERS
EA200300029A1 (en) NEW CARBAMAT COMPOUNDS AND PODOPHILLOTOXIN THIOCARBAMAT, METHOD FOR THEIR PRODUCTION AND CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS
ES8704460A1 (en) 2-Pyridine-thiol derivatives, processes for their preparation and pharmaceutical compositions containing them.
SE9701912D0 (en) Pharmaceutical composition and use thereof
DE69822167D1 (en) ANTIMICROBIAL CONNECTIONS
ES2023760A6 (en) Benzothiazine derivatives, their preparation and their uses as medicines or as intermediates for the synthesis of medicines.
WO2004094396A3 (en) Dihydrothiazine prodrugs of thiazolium agents